Cargando…

Risk of Hospitalization for Cardiovascular Events with β-Blockers in Hypertensive Patients: A Retrospective Cohort Study

INTRODUCTION: β-Blockers are a heterogenous class of drugs that are no longer recommended for initial antihypertension monotherapy due to unfavorable long-term cardiovascular events observed with non-vasodilatory β-blockers. However, the comparative cardiovascular event risk between the vasodilatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basile, Jan, Egan, Brent, Punzi, Henry, Ali, Sanjida, Li, Qian, Patel, Mehul, Neutel, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251822/ https://www.ncbi.nlm.nih.gov/pubmed/30191469 http://dx.doi.org/10.1007/s40119-018-0117-y

Ejemplares similares

Insights on β‐blockers for the treatment of hypertension: A survey of health care practitioners
por: Egan, Brent, et al.
Publicado: (2018)

Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension
por: Ishak, Jack, et al.
Publicado: (2017)

Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017)

Diuretic and β-Blocker in Hypertension—Then What?
por: Ramsay, L. E.
Publicado: (1980)

β-Blockers Improve Presinusoidal Portal Hypertension
por: Sørensen, Michael, et al.
Publicado: (2018)

Cardiovascular outcomes of β‐blocker—calcium channel blocker initial dual therapy vs. other initial dual therapies in Chinese patients with hypertension: A real‐world retrospective study
por: Lin, Junxiong, et al.
Publicado: (2023)

Long‐term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real‐world database: A retrospective cohort study
por: Lee, Wonjae, et al.
Publicado: (2023)

The Real Role of β-Blockers in Daily Cardiovascular Therapy
por: Dézsi, Csaba András, et al.
Publicado: (2017)

Systemic delivery of β-blockers via transdermal route for hypertension
por: Ahad, Abdul, et al.
Publicado: (2015)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

β-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review
por: Tella, Abhinav, et al.
Publicado: (2022)

Comparison of ivabradine plus β-blockers versus β-blocker therapy only
por: Aalbers, J
Publicado: (2010)

Increase use of β-blockers in patients with chronic obstructive pulmonary and cardiovascular disease
por: Yang, Yan-Li, et al.
Publicado: (2021)

Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study
por: Short, Philip M, et al.
Publicado: (2011)

Cochrane corner: beta-blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2018)

Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence
por: McGill, Janet B
Publicado: (2010)

Effectiveness of β-blockers in physically active patients with hypertension: protocol of a systematic review
por: Tučková, Dagmar, et al.
Publicado: (2016)

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
por: Tsujimoto, Tetsuro, et al.
Publicado: (2018)

β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial
por: Booij, Harmen G., et al.
Publicado: (2015)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

β blockers for heart failure
por: Hoes, Arno W
Publicado: (2016)

β1-blocker in sepsis
por: Hasegawa, Daisuke, et al.
Publicado: (2021)

Long-term cardiovascular events in hypertensive patients: full report of the Korean Hypertension Cohort
por: Lee, Jin Young, et al.
Publicado: (2023)

Use of low-dose β(1)-blocker for sinus tachycardia in patients with catecholamine support following cardiovascular surgery: a retrospective study
por: Sakai, Michihiro, et al.
Publicado: (2019)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Predictors of Cardiovascular Events in Hypertensive Patients with High Cardiovascular Risk
por: Tasić, Ivan, et al.
Publicado: (2020)

Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis
por: Tao, Shaohua, et al.
Publicado: (2022)

β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature
por: DiNicolantonio, James J, et al.
Publicado: (2015)

Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension
por: Beaman, Emily Eufaula, et al.
Publicado: (2022)

New Insights into the Management of Hypertension and Cardiovascular Risk with Angiotensin Receptor Blockers: Observational Studies Help Us?
por: Goudev, Assen
Publicado: (2014)

Beta-blockers and the treatment of hypertension: it is time to move on
por: Wiysonge, Charles Shey, et al.
Publicado: (2007)

β(1)-Blockers Lower Norepinephrine Release by Inhibiting Presynaptic, Facilitating β(1)-Adrenoceptors in Normotensive and Hypertensive Rats
por: Berg, Torill
Publicado: (2014)

β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study
por: Lashen, Sameh A, et al.
Publicado: (2022)

Effects of β-blockers therapy on the 28-day and 3-year survival rates of end-stage renal disease patients with cardiovascular disease: a retrospective cohort study
por: Wang, Yong, et al.
Publicado: (2022)

Defining Hypertension by Blood Pressure 130/80 mm Hg Leads to an Impressive Burden of Hypertension in Young and Middle‐Aged Black Adults: Follow‐Up in the CARDIA Study
por: Egan, Brent M.
Publicado: (2018)

Association between topical beta-blockers and risks of cardiovascular and respiratory disease in patients with glaucoma: a retrospective cohort study
por: Chen, Hsin-Yi, et al.
Publicado: (2020)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
por: Kinouchi, Kenichiro, et al.
Publicado: (2011)

Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up
por: Jeong, Han Saem, et al.
Publicado: (2021)

Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review
por: Brewster, Lizzy M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_57bsnecra0gnqqkjksnjtrkvdb